28th Nov 2011 11:47
For immediate release | 28 November 2011 |
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR dealing: Share Incentive Plan
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, announces that following completion of three years of continued employment since the award of Matching Shares under the Share Incentive Plan, the risk of forfeiture attached to these shares has now been removed, resulting in an increase in the beneficial holding of each Director/PDMR as follows:
Name | Matching Shares now transferred to beneficial ownership | Date of transfer to beneficial ownership | Total subsequent beneficial holding | Percentage of share capital | |
Executive Directors: | Jonathan Milner | 1,545 | 27 Nov 11 | 28,098,228 | 15.31% |
Jim Warwick | 1,545 | 27 Nov 11 | 2,939,028 | 1.60% | |
Jeff Iliffe | 1,545 | 27 Nov 11 | 21,228 | 0.01% | |
PDMRs: | Philippe Cotrel | 130 | 27 Nov 11 | 6,224 | 0.003% |
Philippe Cotrel | 135 | 27 Oct 11 | 6,094 | 0.003% | |
Jane Cooke | 1,660 | 27 Oct 11 | 10,872 | 0.01% | |
Ed Ralph | 1,660 | 27 Oct 11 | 382,096 | 0.21% |
For further information please contact:
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer | |
Jeff Iliffe, Chief Financial Officer www.abcamplc.com | |
Numis Securities | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake - Nominated Adviser | |
James Black - Corporate Broking | |
Buchanan Communications | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China) allowing it to serve a global customer base in over 85 countries. Abcam employs over 325 staff across its six operating companies.
Abcam now has an online catalogue of over 81,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.
Related Shares:
ABC.L